{'fraction_non_alphanumeric': 0.03474903474903475, 'fraction_numerical': 0.009652509652509652, 'mean_word_length': 5.92, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Free serum IgE suppression with omalizumab and clinical outcomes in asthma

Introduction: Omalizumab (OMA) dosing was designed to achieve target individual free IgE levels Methods: This analysis assessed FEV1, Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ), Global Evaluation of Treatment Effectiveness (GETE) scores and rescue medication use (RMU) at Week 24 with OMA in 59 patients categorised by free IgE levels ( Results: All patients demonstrated free IgE Conclusion: OMA achieved